Prevalence of high-risk HPV and cervical dysplasia in IUD users and controls: a cross sectional study

References

• Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999;189(1):12–19. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.
   PubMed Web of Science ®Google Scholar
• Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: a review of the literature. Eur J Contracept Reprod Health Care. 2010;15 (sup2):S19–S31. doi: 10.3109/13625187.2010.532999.
   PubMed Web of Science ®Google Scholar
• Buhling KJ, Zite NB, Lotke P, et al. Worldwide use of intrauterine contraception: a review. Contraception. 2014;89(3):162–173. doi: 10.1016/j.contraception.2013.11.011.
   PubMed Web of Science ®Google Scholar
• United Nations DoEaSA, Population Division. Contraceptive Use by Method 2019: data Booklet (ST/ESA/SER.A/435); 2019.
   Google Scholar
• Cortessis VK, Barrett M, Brown Wade N, et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol. 2017;130(6):1226–1236. doi: 10.1097/AOG.0000000000002307.
   PubMed Web of Science ®Google Scholar
• Spotnitz ME, Natarajan K, Ryan PB, et al. Relative risk of cervical neoplasms among copper and levonorgestrel-releasing intrauterine system users. Obstet Gynecol. 2020;135(2):319–327. doi: 10.1097/AOG.0000000000003656.
   PubMed Web of Science ®Google Scholar
• Lekovich JP, Amrane S, Pangasa M, et al. Comparison of human papillomavirus infection and cervical cytology in women using copper-containing and levonorgestrel-containing intrauterine devices. Obstet Gynecol. 2015;125(5):1101–1105. doi: 10.1097/AOG.0000000000000760.
   PubMed Web of Science ®Google Scholar
• Cancercentrum. Nationellt vårdprogram livmoderhalscancerprevention: Regionala cancercentrum. i samverkan; 2022 [updated 2022-11-15; cited 2023 2023-06-14]; Version 4.0:[Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/livmoderhalscancerprevention/vardprogram/.
   Google Scholar
• Pangarkar MA. The bethesda system for reporting cervical cytology. Cytojournal. 2022;19:28. doi: 10.25259/CMAS_03_07_2021.
   PubMed Web of Science ®Google Scholar
• Lindh I, Skjeldestad FE, Gemzell-Danielsson K, et al. Contraceptive use in the nordic countries. Acta Obstet Gynecol Scand. 2017;96(1):19–28. doi: 10.1111/aogs.13055.
   PubMed Web of Science ®Google Scholar
• Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218–226. doi: 10.1093/aje/kwf180.
   PubMed Web of Science ®Google Scholar
• Nielsen A, Iftner T, Munk C, et al. Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women. Sex Transm Dis. 2009;36(10):609–615. doi: 10.1097/OLQ.0b013e3181a96d0e.
   PubMed Web of Science ®Google Scholar
• Shew ML, Ermel AC, Tong Y, et al. Episodic detection of human papillomavirus within a longitudinal cohort of young women. J Med Virol. 2015;87(12):2122–2129. doi: 10.1002/jmv.24284.
   PubMed Web of Science ®Google Scholar
• Skorstengaard M, Lynge E, Napolitano G, et al. Risk of precancerous cervical lesions in women using a hormone-containing intrauterine device and other contraceptives: a register-based cohort study from Denmark. Hum Reprod. 2021;36(7):1796–1807. doi: 10.1093/humrep/deab066.
   PubMed Web of Science ®Google Scholar
• Castellsagué X, Díaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol. 2011;12(11):1023–1031. doi: 10.1016/S1470-2045(11)70223-6.
   PubMed Web of Science ®Google Scholar
• Wulff M, Lalos A. The condom in relation to prevention of sexually transmitted infections and as a contraceptive method in Sweden. Eur J Contracept Reprod Health Care. 20049(2):69–77. doi: 10.1080/13625180410001715636.
   PubMed Web of Science ®Google Scholar
• Bogani G, Sopracordevole F, Ciavattini A, et al. Duration of human papillomavirus persistence and its relationship with recurrent cervical dysplasia. Eur J Cancer Prev. 2023;32(6):525–532. doi: 10.1097/CEJ.0000000000000822.
   PubMed Web of Science ®Google Scholar
• Lam JU, Rebolj M, Dugué PA, et al. Condom use in prevention of human papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen. 2014;21(1):38–50. doi: 10.1177/0969141314522454.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Lukkari-Lax E, Schulze A, et al. Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the mirena extension trial. Am J Obstet Gynecol. 2022;227(6):873.e1–873.e12. doi: 10.1016/j.ajog.2022.09.007.
   PubMed Web of Science ®Google Scholar
• Monsonego J, Cox JT, Behrens C, et al. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. Gynecol Oncol. 2015;137(1):47–54. doi: 10.1016/j.ygyno.2015.01.551.
   PubMed Web of Science ®Google Scholar
• WHO International Agency for Research on Cancer. Estimated number of new cases in 2020, worldwide, females, all ages. 2020. Access date 2021-05-17.
   Google Scholar
• Bruni L, Saura-Lázaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021;144:106399. doi: 10.1016/j.ypmed.2020.106399.
   PubMed Web of Science ®Google Scholar
• Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the royal college of general practitioners’ oral contraception study. Am J Obstet Gynecol. 2017;216(6):580.e1-580–e9. doi: 10.1016/j.ajog.2017.02.002.
   Web of Science ®Google Scholar